{
    "organizations": [],
    "uuid": "86e96477f1735dab8fba5ef270b78f35420af37e",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-solasia-pharma-says-termination-of/brief-solasia-pharma-says-termination-of-clinical-trials-phase-1-of-sp-04-idUSL4N1PZ37R",
    "ord_in_thread": 0,
    "title": "BRIEF-Solasia Pharma says termination of clinical trials phase 1 of SP-04",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 9 (Reuters) - Solasia Pharma KK\n* Says it announces termination of SP-04 clinical trials phase 1, for treatment of peripheral nerves disability\nSource text in Japanese: goo.gl/inouVL\nFurther company coverage: (Beijing Headline News)\n ",
    "published": "2018-02-09T16:12:00.000+02:00",
    "crawled": "2018-02-10T14:17:47.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "solasia",
        "pharma",
        "kk",
        "say",
        "announces",
        "termination",
        "clinical",
        "trial",
        "phase",
        "treatment",
        "peripheral",
        "nerve",
        "disability",
        "source",
        "text",
        "japanese",
        "company",
        "coverage",
        "beijing",
        "headline",
        "news"
    ]
}